Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 6, 1996, Pages 619-623

  Yeilding, Allen ^a   Bertoli, Luigi ^b   Eisenberg, Peter ^c   Plezia, Patricia ^d   Modiano, Manuel R ^d   Alberts, David S ^g   Khojasteh, Ali ^e   Cramer, Michael B ^f   Hahne, William F ^f  

^a Carraway Cancer Center   (United States)

^b Brookwood Medical Center Birmingham   (United States)

^c Marin Oncology Associates   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f Marion Merrell Dow   (United States)

^g NONE

Author keywords

5 HT 3; antagonist; Antiemetic; Chemotherapy induced emesis; Cisplatin; Clinical trial; Dolasetron; Emesis; Nausea

Indexed keywords

CISPLATIN; DOLASETRON MESILATE; DRUG METABOLITE; HYDRODOLASETRON; UNCLASSIFIED DRUG;

ANTIEMETIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; CISPLATIN; DIARRHEA; DOUBLE-BLIND METHOD; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HEART RATE; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUINOLIZINES; REMISSION INDUCTION; SAFETY; VOMITING;

EID: 0029852564     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199612000-00018     Document Type: Article

References (16)

1. Gralla RJ. Current issues in the management of nausea and vomiting. Ann Oncol 1993;4(suppl 3):S3-S7.
2. 3 antagonists. Support Care Cancer 1994;2:286-92.
3. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905-9.
4. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma × glioma cells. Eur J Pharmacol 1992;219:9-13.
5. 3 receptor antagonist. Drug Dev Res 1995;34:289-96.
6. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics. I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992;13:693-701.
7. Heck K, Holmes GB, Adams MA, Hunt TL, Hahne W. A double-blind, placebo-controlled, dose-rising tolerance study of intravenous MDL 73,147EF in normal volunteers [Abstract]. Clin Pharmacol Ther 1992;51:186.
8. Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 1995 (in press).
9. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 1994;17:97-102.
10. 3 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 1993;4:481-4.
11. Kris MG, Grunberg SM, Gralla RJ, et al. Dose-ranging evaluation of the serotonin antagonist dolasetron in patients receiving high-dose cisplatin. J Clin Oncol 1994;12:1045-9.
12. Merrouche Y, Catimel G, Rebattu P, et al. A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antag onist in cancer patients receiving emetogenic chemotherapy. Ann Oncol 1994;5:549-51.
13. Harman GS, Omura GA, Ryan K, et al. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1995 (in press).
14. Kasimis B, Tapazoglou E, Schulman P, et al. A double-blind, randomized study of two different dose regimens of intravenous (IV) dolasetron (DOL) in patients (PTS) receiving high dose cisplatin (CDDP) chemotherapy [Abstract]. Proc Am Soc Clin Oncol 1994;13:446.
15. Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991;41:574-95.
16. Plosker GL, Goa KL. Granisetron: a review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 1991;42:805-24.